Related Experiment Video
Updated: Jun 23, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Position statement on the appropriate usage of biologic therapies for asthma in South Africa
R N van Zyl-Smit1, M Greenblatt2, C Smith3
1Division of Pulmonology and UCT Lung Institute, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape own, South Africa.
Abstract:
Biologic therapies such as monoclonal antibodies are highly effective in reducing disease burden (exacerbations/corticosteroid usage/ hospitalisation) in patients with severe asthma. These medications are currently prohibitively expensive for widespread use compared with standard inhaled and oral therapy. They are indicated for patients with predominantly type 2-high inflammation. Judicious use of biologic therapies in the South African context is imperative given the country's limited healthcare resources. The prescription and clinical use of these therapies within the scope of the South African Health Products Regulatory Authority registered indications therefore require clear guidance and appropriate preparatory optimisation to ensure that the appropriate patients receive the correct medication within an acceptable time frame. Not all patients with difficult-to-treat, or nominally designated as severe, asthma require a biologic therapy in order to be optimally controlled. Simple attention to basic asthma therapeutic principles and treatment of comorbid disease by a clinician with a special interest in asthma may be all that is required. This position statement, written by senior clinicians from the South African Thoracic Society (SATS), is intended to supplement the SATS asthma treatment recommendation of 2021. It provides clear guidance on the appropriate assessment of patients being considered for biologic therapy and clarifies which background medication is required to initiate a biologic therapy in an evidence-based manner. A balanced consideration of side-effects, scientific evidence and cost is essential to prevent unjustified harm to patients by delaying or denying access to biologic therapy. A process to endorse biologic therapy has been created in parallel, and forms are available from SATS, along with registration in the severe asthma registry to support clinicians in appropriate assessment and justification for prescription.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma-IV: Nursing Management
First, in...